All Stories

  1. Pulmonary diffusing capacity and dyspnoea following COVID-19: Insights from multicentre datasets
  2. The role of simple pulmonary function testing in unravelling the presence of respiratory muscular dysfunction in two patients with interstitial lung diseases
  3. Early career members’ committee updates and reflections of an ECMC Chair and co-Chair mandates
  4. Enhanced detection of patients with previous COVID-19: superiority of the double diffusion technique
  5. GLI Global equations for ILD patients: Shall we keep the baby, the bathwater, or both?
  6. The CheckMate 816 trial: a milestone in neoadjuvant chemoimmunotherapy of nonsmall cell lung cancer
  7. The CT revolution: the role of PIOPED II in establishing CT pulmonary angiography as the reference standard for pulmonary embolism diagnosis
  8. Thoracic ultrasound for pneumothorax and infectious effusion: from equine beginnings to clinical cornerstone
  9. Holistic management of patients with progressive pulmonary fibrosis
  10. Experience of being chair and co-chair of the ECMC and reasons why you should be the NEXT
  11. Reply to Noel-Savina and collaborators: DM and VC impairment after COVID-19
  12. The exposome concept: how has it changed our understanding of environmental causes of chronic respiratory diseases?
  13. What to expect from the ERS International Congress 2023
  14. International use of objective structured clinical examinations in respiratory training: a European Respiratory Society early career member survey
  15. Balloon pulmonary angioplasty: are we there yet? Lessons learned and unanswered questions
  16. The road to hell is paved with good intentions: a look back at the PANTHER-IPF trial
  17. European Respiratory Society International Congress 2021: Highlights from the Respiratory clinical care and physiology assembly
  18. Objective structured clinical examinations (OSCEs) for students’ training and assessment in the French respiratory medicine departments in 2021: An overview
  19. Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients
  20. Multiparameter analysis of vascular remodeling in post-acute sequelae of COVID-19
  21. Estimation of Regional Pulmonary Compliance in Idiopathic Pulmonary Fibrosis Based on Personalized Lung Poromechanical Modeling
  22. Is there a shift of the oxygen-hemoglobin dissociation curve in COVID-19?
  23. Cardiopulmonary exercise testing in interstitial lung diseases and the value of ventilatory efficiency
  24. Pathophysiology of pulmonary function anomalies in COVID-19 survivors
  25. Highlights of the ERS Lung Science Conference and Sleep and Breathing Conference 2021 and the new ECMC members
  26. Gender Differences in Idiopathic Pulmonary Fibrosis: Are Men and Women Equal?
  27. The Affinity of Hemoglobin for Oxygen Is Not Altered During COVID-19
  28. Predictors of negative SARS-CoV-2 PCR despite diagnosis of COVID-19 and association with outcome
  29. Predictors of characteristics associated with negative first SARS-CoV-2 PCR testing despite final diagnosis of COVID-19, and association with treatment and outcomes. The COVID-19 RT-PCR Study
  30. Late Breaking Abstract - The affinity of haemoglobin for oxygen is not altered in the course of Covid-19
  31. Predictors of mortality in fibrosing pulmonary sarcoidosis
  32. ER Stress is Involved in Epithelial-To-Mesenchymal Transition of Alveolar Epithelial Cells Exposed to a Hypoxic Microenvironment
  33. HIF-1α triggers ER stress and CHOP-mediated apoptosis in alveolar epithelial cells, a key event in pulmonary fibrosis
  34. Endothelial Colony-Forming Cells Do Not Participate to Fibrogenesis in a Bleomycin-Induced Pulmonary Fibrosis Model in Nude Mice
  35. A simple prognostic tool for idiopathic pulmonary fibrosis (IPF)
  36. Natural history of idiopathic pulmonary fibrosis (IPF) associated with obstructive sleep apnea (OSA) with or without continuous positive airway pressure (CPAP)
  37. ER stress is involved in alveolar epithelial cell dysfunction in hypoxia
  38. Intermittent Hypoxia Increases the Severity of Bleomycin-Induced Lung Injury in Mice
  39. Adding Azathioprine to Remission-Induction Glucocorticoids for Eosinophilic Granulomatosis With Polyangiitis (Churg-Strauss), Microscopic Polyangiitis, or Polyarteritis Nodosa Without Poor Prognosis Factors
  40. Obstructive sleep apnoea and related comorbidities in incident idiopathic pulmonary fibrosis
  41. Does training respiratory physicians in clinical respiratory physiology and interpretation of pulmonary function tests improve core knowledge?
  42. Mesenchymal stem cells protect from hypoxia-induced alveolar epithelial-mesenchymal transition
  43. Adult Onset Asthma and Periocular Xanthogranuloma (AAPOX), a Rare Entity With a Strong Link to IgG4-Related Disease
  44. Lung function testing: Knowledge of French pulmonology residents
  45. Hypoxia inhibits semicarbazide-sensitive amine oxidase activity in adipocytes
  46. Conditioned media from mesenchymal stromal cells restore sodium transport and preserve epithelial permeability in an in vitro model of acute alveolar injury
  47. Hypoxia-Induced Inhibition of Epithelial Na+Channels in the Lung. Role of Nedd4-2 and the Ubiquitin-Proteasome Pathway
  48. Adult-Onset Asthma Associated With Periocular Xanthogranuloma
  49. Chronic beryllium disease: azathioprine as a possible alternative to corticosteroid treatment
  50. Sarcoïdose : l’atteinte des hormones à dépendance antéhypophysaire est insuffisamment diagnostiquée
  51. Imaging of sarcoidosis of the airways and lung parenchyma and correlation with lung function
  52. Mechanism Of Epithelial Na+ Channel (ENaC) Inhibition By Hypoxia In Alveolar Epithelial Cells
  53. Pulmonary Hypertension Complicating Interstitial and Granulomatous Lung Diseases
  54. Innovations thérapeutiques de la fibrose pulmonaire idiopathique
  55. Treatment of recurrent respiratory papillomatosis lung involvement by cidofovir infusion
  56. Apports de l’analyse minéralogique en pratique clinique
  57. Pneumopathie d’hypersensibilité : nouveaux visages et concepts actuels